Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis



Rating:

Share or cite this content

Citations should be made in the following way:
E. Dementyeva (Moscow, Russian Federation), V. Aksenova (Moscow, Russian Federation), A. Kazakov (Moscow, Russian Federation), N. Klevno (Moscow, Russian Federation). Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants. 2285

Member's Comments

No comment yet.

Related content which might interest you: Screening and monitoring of TB infection in rheumatological patients on biologics therapy Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 Screening and monitoring of tuberculosis in patients on biologics treatment Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Source: Eur Respir J 2006; 28: Suppl. 50, 128s Year: 2006 Design of tuberculosis treatment regimens for drug-resistant and intolerant patients – patient and clinician perspectives Source: International Congress 2018 – CC4 Tuberculosis Year: 2018 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART Source: Breathe 2008; 5: 274 Year: 2009 Use of molecular-genetic methods in diagnostics and therapy of a tuberculosis (TB) at patients with HIV Source: Annual Congress 2010 - Tuberculosis in special populations Year: 2010 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Appreciation efficiency of standard and alternative antituberculosis preventive therapy in children from different tuberculosis infection sources Source: Eur Respir J 2006; 28: Suppl. 50, 28s Year: 2006 Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 New approaches for evaluation of treatment effectiveness among patients with pulmonary TB under DOTS implemented conditions Source: Eur Respir J 2002; 20: Suppl. 38, 368s Year: 2002 Experience of isofon use for therapy and chemoprophylaxis of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 The pharmacotherapy options for the intensive treatment phase in patients with primarily diagnosed pulmonary tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Tuberculosis screening in patients receiving biological therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015